Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Current Deferred Revenue (2016 - 2023)

Historic Current Deferred Revenue for BeOne Medicines (BEIGF) over the last 8 years, with Q2 2023 value amounting to $159.0 million.

  • BeOne Medicines' Current Deferred Revenue fell 266.96% to $159.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $159.0 million, marking a year-over-year decrease of 266.96%. This contributed to the annual value of $213.9 million for FY2022, which is 2871.3% down from last year.
  • According to the latest figures from Q2 2023, BeOne Medicines' Current Deferred Revenue is $159.0 million, which was down 266.96% from $185.5 million recorded in Q1 2023.
  • In the past 5 years, BeOne Medicines' Current Deferred Revenue ranged from a high of $300.0 million in Q4 2021 and a low of $17.5 million during Q1 2019
  • Moreover, its 4-year median value for Current Deferred Revenue was $159.0 million (2023), whereas its average is $141.4 million.
  • The largest annual percentage gain for BeOne Medicines' Current Deferred Revenue in the last 5 years was 15689.18% (2022), contrasted with its biggest fall of 2871.3% (2022).
  • Over the past 4 years, BeOne Medicines' Current Deferred Revenue (Quarter) stood at $17.5 million in 2019, then surged by 1613.89% to $300.0 million in 2021, then fell by 28.71% to $213.9 million in 2022, then fell by 25.64% to $159.0 million in 2023.
  • Its Current Deferred Revenue stands at $159.0 million for Q2 2023, versus $185.5 million for Q1 2023 and $213.9 million for Q4 2022.